Immunotherapy earns its spot in the ranks of cancer therapy

Dual biological effects of the cytokines interleukin-10 and interferon-γ

(2011) Cailin Moira Wilke et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

The Inhibitory Role of B7-H4 in Antitumor Immunity: Association with Cancer Progression and Survival

(2011) Changjun He et al.   Clinical & Developmental Immunology

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

(2011) J. Yuan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

(2011) O. S. Qureshi et al.   SCIENCE

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Improved Endpoints for Cancer Immunotherapy Trials

(2010) A. Hoos et al.   JNCI-Journal of the National Cancer Institute

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Development of the Anti–CTLA-4 Antibody Tremelimumab

(2010) Antoni Ribas   SEMINARS IN ONCOLOGY

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD

Fine tuning the immune response through B7-H3 and B7-H4

(2009) Kyung H. Yi et al.   IMMUNOLOGICAL REVIEWS

CD28 and CTLA-4 coreceptor expression and signal transduction

(2009) Christopher E. Rudd et al.   IMMUNOLOGICAL REVIEWS

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

(2009) Loise M. Francisco et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

(2009) Karl S. Peggs et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Vaccine trials in melanoma—time for reflection

(2009) Alexander M. M. Eggermont   Nature Reviews Clinical Oncology

Human prostate-infiltrating CD8+T lymphocytes are oligoclonal and PD-1+

(2009) Karen S. Sfanos et al.   PROSTATE

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

(2008) Shawn D Blackburn et al.   NATURE IMMUNOLOGY

CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

(2008) C. I. Liakou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CTLA-4 Control over Foxp3+ Regulatory T Cell Function

(2008) K. Wing et al.   SCIENCE